- Companies
- H1.co
Last H1.co valuation
$773M
Series C · Jun 2022
Last H1.co funding round
$40M
Undisclosed stage · May 2026
Cumulative funding H1.co raised
$234M
across 5 funding rounds
Key investors in H1.co
Menlo Ventures
Transformation Capital
dRx Capital
Y Combinator
Lux Capital
IVP
About H1.co
H1.co is a New York-based healthcare intelligence platform founded in 2017 that aggregates data on over 4 million healthcare professionals and 1,000 institutions. The service enables life sciences companies, hospitals, and health systems to access provider insights, clinical trial matching, and benchmarking tools. H1 connects stakeholders through its HCP Universe database and partners with entities like Pfizer and Mayo Clinic.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$773M (Jun 2022)
H1.co Valuation
H1.co is currently valued at $773M, based on its Series C in June 2022.
The $23M round included Menlo Ventures, Novartis, Goldman Sachs Asset Management and Transformation Capital.
H1.co's valuation has moved from $773M at its Series C in November 2021 to $773M in June 2022, across 2 priced rounds.
H1.co valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2022 | Series C | $773M |
| Nov 2021 | Series C | $773M |
H1.co Funding History
H1.co has raised a total of $234M across 5 funding rounds.
H1.co's first fundraising round was a $13M Series A in March 2020. The most recent completed round was a $40M undisclosed-stage round in May 2026.
H1.co funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| May 2026 | Undisclosed stage | CVS Health Ventures (lead) | $40M | - | H1 received a $40 million investment in a round led by CVS Health Ventures on May 28, 2026. The round was described as a strategic investment by the corporate venture capital arm of CVS Health, aimed at supporting health care innovation and digital disruption. The announcement did not specify a valuation or deal structure beyond the lead investor and investment amount. The investment follows a prior collaboration between H1 and CVS Health Ventures, which was cited as part of the rationale for the funding. H1 said the capital would support expansion of its AI healthcare data infrastructure and provider-directory capabilities, with an emphasis on making health care information more accessible and useful. CVS Health Ventures was described as a corporate venture fund focused on early-stage and growth-stage companies in health care. H1 is a healthcare data and software company focused on physician and provider data, including AI-enabled products for healthcare provider discovery and infrastructure. The company’s materials and related coverage characterize the business as building data products used to improve access to provider information and support healthcare workflows. |
| Jun 2022 | Series C | Menlo Ventures; Novartis; Goldman Sachs Asset Management; Transformation Capital | $23M | $773M | H1.co is a health tech platform that connects healthcare professionals, clinical, science, and research information, serving as a massive digital professional database and data analytics platform linking healthcare professionals with life science companies like pharmaceutical, biotech, and medical device firms, essentially functioning as LinkedIn for the pharmaceutical and biotech industries. The company supports over 250 customers, including top pharmaceutical companies, and had grown from under 10 employees as a bootstrapped Y Combinator graduate in January 2020 to more than 600 employees globally by June 2022, with rapid scaling including two acquisitions in the prior year. In June 2022, H1 secured a Series C extension of $23 million in equity plus $10 million in debt, bringing the total Series C to $123 million following the original $100 million round in November 2021 led by Altimeter Capital with participation from Goldman Sachs Asset Management, Menlo Ventures, Transformation Capital, Flex Capital, IVP, Lux Capital, and LeadEdge. This extension maintained the post-money valuation at $773 million on the same terms as the initial Series C close, extending runway amid volatile markets to fuel growth, product development, network expansion, and hiring toward becoming the core global healthcare network. Traction included approximately 140% year-over-year ARR growth as of Q1 2022, with the company on pace to double revenue in 2022 and over 50% growth in less than two quarters post-initial Series C. H1 has raised $305 million across 8 rounds total by 2024, with recognition as an innovator on lists like Forbes' Best Startup Employers 2022 and NYC Digital Health 100. |
| Nov 2021 | Series C | Altimeter Capital (lead); Menlo Ventures; IVP; Lead Edge Capital; Lux Capital; dRx Capital; Flex Capital; Goldman Sachs Asset Management; Transformation Capital | $100M | $773M | H1 operates a global platform connecting healthcare professionals, providing comprehensive data on doctors worldwide, including public, proprietary, and private sources to help pharma, life sciences, hospitals, and academic centers identify key opinion leaders, clinical research opportunities, and make informed decisions. Products include Explorer, HCP Universe, Trial Landscape, and Carevoyance, serving over 100 clients such as seven of the top 10 pharmaceutical companies like Novartis and AstraZeneca, plus institutions like Columbia and UPenn. On November 16, 2021, H1 raised a $100 million Series C round led by Altimeter Capital, with new investors Goldman Sachs Asset Management and Flex Capital, and participation from existing investors IVP, Menlo Ventures, Transformation Capital, Lux Capital, and Lead Edge Capital. The funding aimed to expand data and network, product development, hiring, and go-to-market efforts to pharma and life sciences. In June 2022, H1 secured a $23 million Series C extension, bringing the total Series C to $123 million at a $773 million valuation, extending runway amid volatile markets at the same terms. At the time of the Series C announcement, H1 reported over 250% year-to-date growth in annual recurring revenue (ARR) in 2021, with about 100 clients and strong traction in its first use case for key opinion leader identification. By Q1 2022, ARR growth reached approximately 140% year-over-year, supported by network effects and increasing demand for healthcare data. The company, which graduated from Y Combinator in 2020 as a bootstrapped startup under 10 employees, had raised about $71 million prior and grown to over 200 employees with offices in 5 global locations across 84 countries. H1's flywheel accelerates with more healthcare professionals and industry engagement, positioning it as a must-have data source in a fast-changing healthcare environment. Investors highlighted the massive opportunity in life sciences data, with the digital health market projected to reach $426.8 billion by 2027. |
| Dec 2020 | Series B | IVP (lead); Menlo Ventures (lead); Y Combinator; Lead Edge Capital; Lux Capital; dRx Capital; Transformation Capital | $58M | - | H1.co (H1 Insights) is a healthcare data platform described as the LinkedIn for the healthcare industry, maintaining a database of over 8 million healthcare professional profiles. It serves pharmaceutical, biotech, and life sciences companies by enabling connections with healthcare professionals, particularly through services for medical affairs departments. The company graduated from Y Combinator and demonstrated strong growth, with 350% year-over-year increase and 35 pharmaceutical customers as of April 2020. In February 2020, H1 raised $12.9 million in a Series A round led by Menlo Ventures, with participation from Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, Novartis dRx, and Underscore VC. This funding came shortly after Y Combinator graduation and was not repriced despite the onset of the COVID-19 pandemic, and the company was generating multiple millions of dollars in revenue at the time. H1 continued operations amid COVID-19 disruptions, with pharma companies pausing clinical trials but still engaging medical affairs services. Earlier traction included rapid database expansion and customer adoption, positioning H1 to leverage AI and machine learning for healthcare impact. Plans post-Series A included a massive hiring spree. |
| Mar 2020 | Series A | Menlo Ventures (lead); Jeff Hammerbacher; ClearPoint Investment Partners; Y Combinator; Liquid 2 Ventures; dRx Capital; Underscore VC; Baron Davis Enterprises | $13M | - | H1 is a healthcare data platform and professional networking service often described as 'LinkedIn for healthcare.' The company maintains digital profiles and data analytics on over 8 million healthcare professionals and 16,000 institutions across 70+ countries, updated weekly, with comprehensive information including expertise, educational history, affiliations, research, publications, clinical trials, patents, and grants. The company's database captures information on over 95% of healthcare professional-patient interactions in the U.S. In February 2020, H1 closed a $12.9 million Series A round led by Menlo Ventures and including investors Novartis DRX, Y Combinator, Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, and Underscore VC. At the time of the round, H1 reported 350% revenue growth year-over-year and counted over 35 pharmaceutical companies as customers. The company used the capital to expand its sales, product design, and engineering teams, and to pursue expansion into new market segments including hospitals, health systems, and the provider community. By June 2022, H1 had raised a total of $193 million across multiple rounds and achieved a valuation of $773 million in its Series C extension. |
Who has invested in H1.co?
17 investors have backed H1.co across its funding rounds, including Menlo Ventures, Transformation Capital, dRx Capital, Y Combinator, Lux Capital and IVP.
Lead investors include CVS Health Ventures, Altimeter Capital, IVP and Menlo Ventures.
H1.co Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Mar 2020 | ||
| 3 | Participant | Mar 2020 | ||
| 3 | Participant | Dec 2020 | ||
| 2 | Lead | Dec 2020 | ||
| 2 | Participant | Mar 2020 | ||
| 2 | Participant | Dec 2020 | ||
| 2 | Participant | Dec 2020 | ||
| 2 | Participant | Nov 2021 | ||
| 1 | Participant | Mar 2020 | ||
| 1 | Participant | Mar 2020 | ||
| 1 | Participant | Mar 2020 | ||
| 1 | Participant | Jun 2022 | ||
| 1 | Lead | Nov 2021 | ||
This data is available for Pro users. Sign up to see all 17 H1.co investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by H1.co
H1.co has acquired 5 companies to date.
Last acquisition by H1.co was on September 9th 2026. H1.co acquired Defacto Health for undisclosed valuation.
Latest Acquisitions by H1.co
| Description | Healthcare data transparency | VEDA Data Solutions is a Washington, D.C.-headquartered provider of automated data science and machine learning platforms for healthcare payers and provider networks. Founded in 2015, it integrates predictive analytics into existing dashboards for risk stratification, utilization forecasting, and population health management. VEDA processes claims, EHR, and social determinants data to deliver models for readmission prevention and care gap closure. The platform supports Medicare Advantage plans and ACOs, deploying solutions at organizations like Humana and regional health systems. | Ribbon Health is a New York-headquartered healthcare API platform delivering provider data to payers and digital health firms. It maintains directories with verified credentials, specialties, and availability for 1.5 million U.S. clinicians. Ribbon Health powers referrals, prior authorizations, and navigation apps for Aetna and Teladoc partners. | Faculty Opinions is a literature curation service where over 8,000 life sciences experts select and annotate key research articles. Launched as part of the F1000 ecosystem, it covers biology, medicine, and clinical research with detailed commentary on methodologies and implications. The platform organizes publications into collections by topic and provides researcher-validated recommendations. Cambridge-based, Faculty Opinions aids scientists in navigating high-impact studies efficiently. | |
| HQ Country | |||||
| HQ City | Washington, DC | Madison, WI | New York City, NY | London | |
| Deal Date | 9 Sep 2026 | 3 Jun 2025 | 12 Dec 2024 | 16 Feb 2022 | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all H1.co acquisitions and their M&A valuation multiples. Start Free Trial | |||||
H1.co Competitors
H1.co competitors include listed companies like Clover Health and SOPHiA Genetics, and private ones like Proof, Nansen, Elixir and Codat.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $1.9B | ($84M) | $2.4B | 0.8x | ||
| Private | - | - | $760M | - | ||
| Private | - | - | $750M | - | ||
| Private | - | - | $800M | - | ||
| Publicly listed | $77M | ($65M) | $726M | 7.5x | ||
| Private | - | - | $825M | - |
H1.co Public Comps
H1.co is still privately-owned, but its public comps include SOPHiA Genetics, Veradigm, CARE Ratings, GlobalData, Bayzed Health Group, Finatext, Yidu Tech, TaiDoc Technology, Omada Health and Certara.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $77M | ($65M) | 8.8x | 7.5x | (10.4x) | (18.8x) | |||
| $588M | $54M | 0.9x | 0.9x | 9.8x | 6.8x | |||
| $49M | $21M | 9.2x | 9.9x | 21.5x | 20.5x | |||
| $433M | $140M | 1.7x | 1.7x | 5.3x | 5.0x | |||
| $167M | $18M | 3.0x | - | 28.4x | - | |||
| $71M | $13M | 6.3x | 5.4x | 34.1x | - | |||
| $122M | ($4M) | 1.4x | 1.2x | (45.0x) | 7.7x | |||
| $132M | $58M | 2.1x | - | 4.8x | - | |||
This data is available for Pro users. Sign up to see all H1.co competitors and their valuation data. Start Free Trial | ||||||||
Common questions about H1.co
| When was H1.co founded? | H1.co was founded in 2017. |
| Where is H1.co headquartered? | H1.co is headquartered in New York City, NY, United States. |
| Is H1.co publicly listed? | No, H1.co is a private, VC-backed company. |
| What is H1.co's valuation? | H1.co was last valued at $773M in its Series C in June 2022. |
| How much funding has H1.co raised? | H1.co has raised $234M across 5 funding rounds. |
| What was H1.co's last funding round? | H1.co's last funding round was a $40M undisclosed-stage round in May 2026, led by CVS Health Ventures. |
| Who are H1.co's investors? | H1.co's investors include Menlo Ventures, dRx Capital, Transformation Capital, IVP, Y Combinator, Lead Edge Capital, Lux Capital, Goldman Sachs Asset Management, Jeff Hammerbacher, ClearPoint Investment Partners and 7 others. |
| Which companies are comparable to H1.co? | Companies comparable to H1.co include Clover Health, Proof, Nansen, Elixir, SOPHiA Genetics and Codat. |
| How many companies has H1.co acquired? | H1.co has acquired 5 companies, including Defacto Health, VEDA Data Solutions, Ribbon Health, Faculty Opinions and Carevoyance. |
See companies similar to H1.co
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




